Alternative dosing of exemestane in postmenopausal women with stage 0-II ER-positive breast cancer: a randomized presurgical trial
Ended Awarded Last action
- Contract number
- HHSN26100008
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,581,195
Award facts
- Opportunity
-
- T2014 Solicitation number
- Contract value 94% obligated
-
- $1,581,194.95 Current, with exercised options
- $1,686,205.95 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77030, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$598 | |
| Change Order | $0 | |
| Exercise an Option | $12,938 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $30,339 | |
| Exercise an Option | $865,213 | |
| Change Order | $8,600 | |
| Original award | $664,703 |
About this award
This is a $1,686,205.95 delivery order contract awarded by the National Cancer Institute (NCI) to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct a randomized pre-surgical clinical trial evaluating alternative dosing regimens of the cancer drug exemestane in postmenopausal women with early-stage estrogen receptor-positive breast cancer. The contract is part of NCI's Cancer Prevention Agent Development Program, which supports early phase clinical research on new cancer prevention and treatment strategies. As a component of the University of Texas System, MD Anderson has extensive experience as both a prime recipient and subrecipient of federal research contracts and grants from agencies like NIH, DoD, and VA. This contract does not have a small business set-aside designation.
Quick answers
Who was awarded contract HHSN26100008?
HHSN26100008 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on August 1, 2015.
How much is contract HHSN26100008 worth?
The government has obligated $1,581,195 on HHSN26100008. Its potential value, with all options, is $1,686,206.
Is contract HHSN26100008 an order under another contract?
Yes. HHSN26100008 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100008 competed?
The extent of competition for HHSN26100008 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award